David Thomson Biography and Net Worth

EVP of MannKind

David joined MannKind after working on the merger that formed the company from three independent biopharma companies. Since January 2002, he has been responsible for its legal and compliance matters. As the longest-serving MannKind employee, David understands the importance of carrying on Al Mann’s legacy of helping people live fuller, healthier lives.

How he lives life more humann:
Outside of the office, David volunteers for the American Youth Soccer Organization (AYSO).

What is David Thomson's net worth?: The estimated net worth of David Thomson is at least $5.98 million as of May 21st, 2024. Mr. Thomson owns 873,616 shares of MannKind stock worth more than $5,984,270 as of December 21st. This net worth estimate does not reflect any other assets that Mr. Thomson may own. Additionally, Mr. Thomson receives an annual salary of $862,230.00 as EVP at MannKind. Learn More about David Thomson's net worth.
How old is David Thomson?: Mr. Thomson is currently 57 years old. There are 8 older executives and no younger executives at MannKind. The oldest executive at MannKind is Mr. John F. Bedard, Senior Vice President of Worldwide Regulatory Affairs, who is 74 years old. Learn More on David Thomson's age.
What is David Thomson's salary?: As the EVP of MannKind Co., Mr. Thomson earns $862,230.00 per year. There are 2 executives that earn more than Mr. Thomson. The highest earning executive at MannKind is Dr. Michael E. Castagna Pharm.D., CEO & Director, who commands a salary of $1,530,000.00 per year. Learn More on David Thomson's salary.
How do I contact David Thomson?: The corporate mailing address for Mr. Thomson and other MannKind executives is 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362. MannKind can also be reached via phone at (818) 661-5000 and via email at [email protected]. Learn More on David Thomson's contact information.
Has David Thomson been buying or selling shares of MannKind?: David Thomson has not been actively trading shares of MannKind during the last ninety days. Most recently, David Thomson sold 23,537 shares of the business's stock in a transaction on Tuesday, May 21st. The shares were sold at an average price of $4.66, for a transaction totalling $109,682.42. Following the completion of the sale, the executive vice president now directly owns 873,616 shares of the company's stock, valued at $4,071,050.56. Learn More on David Thomson's trading history.
Who are MannKind's active insiders?: MannKind's insider roster includes Steven Binder (CFO), Michael Castagna (CEO), Alejandro Galindo (Insider), David Thomson (EVP), and Stuart Tross (Insider). Learn More on MannKind's active insiders.
Are insiders buying or selling shares of MannKind?: In the last twelve months, insiders at the biopharmaceutical company sold shares 10 times. They sold a total of 415,227 shares worth more than $2,696,774.66. The most recent insider tranaction occured on November, 22nd when Director Steven B Binder sold 67,536 shares worth more than $465,323.04. Insiders at MannKind own 3.0% of the company. Learn More about insider trades at MannKind.
Information on this page was last updated on 11/22/2024.

David Thomson Insider Trading History at MannKind

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/21/2024	Sell	23,537	$4.66	$109,682.42	873,616
8/28/2023	Sell	8,100	$4.78	$38,718.00	798,835
5/24/2023	Sell	95,576	$4.68	$447,295.68	735,263
8/29/2022	Sell	7,000	$3.67	$25,690.00	726,035
8/27/2021	Sell	4,100	$4.64	$19,024.00	567,391
2/5/2015	Sell	80,000	$7.00	$560,000.00
11/24/2014	Sell	118,114	$6.14	$725,219.96
8/7/2014	Sell	30,000	$8.16	$244,800.00
6/26/2014	Sell	30,000	$10.51	$315,300.00
6/4/2014	Sell	133,000	$9.95	$1,323,350.00
12/11/2013	Sell	150,000	$5.00	$750,000.00	83,752
8/28/2013	Sell	19,204	$5.78	$110,999.12	40,082

David Thomson Buying and Selling Activity at MannKind

MannKind Company Overview

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Today's Range

Now: $6.85

$6.30

$7.07

50 Day Range

MA: $6.75

$5.93

$7.44

2 Week Range

Now: $6.85

$3.17

$7.63

Volume

7,214,138 shs

Average Volume

2,616,986 shs

Market Capitalization

$1.89 billion

P/E Ratio

97.86

Dividend Yield

N/A

Beta

1.28

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...

I put all the details together for you here — but please hurry.

David Thomson Biography and Net Worth

What is David Thomson's net worth?

How old is David Thomson?

What is David Thomson's salary?

How do I contact David Thomson?

Has David Thomson been buying or selling shares of MannKind?

Who are MannKind's active insiders?

Are insiders buying or selling shares of MannKind?